Literature DB >> 10595907

Beta-catenin mutations are frequent in human hepatocellular carcinomas associated with hepatitis C virus infection.

H Huang1, H Fujii, A Sankila, B M Mahler-Araujo, M Matsuda, G Cathomas, H Ohgaki.   

Abstract

Hepatocellular carcinoma (HCC) is one of the most common fatal cancers worldwide. Hepatitis B virus and hepatitis C virus infections, exposure to aflatoxin, and excessive intake of alcohol have been identified as major risk factors. However, the molecular mechanisms underlying their development are still poorly understood. Recently, beta-catenin, one of the key components of the Wnt signaling pathway, has been found to be mutated in about 20% of HCCs, suggesting a role of the Wnt pathway in their development. In this study, we examined beta-catenin and APC mutations in 22 HCCs associated with HCV infection, using single-strand conformation polymorphism (SSCP) followed by direct DNA sequencing. beta-Catenin mutations were found in nine (41%) cases, but no APC mutations were found. beta-Catenin immunohistochemistry revealed nuclear accumulation of beta-catenin protein in all nine tumors with a beta-catenin mutation and two additional tumors without a mutation. These results suggest that activation of the Wnt signaling pathway by beta-catenin mutation contributes significantly to the hepatocellular carcinogenesis associated with HCV infection.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10595907      PMCID: PMC1866943          DOI: 10.1016/s0002-9440(10)65496-x

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  54 in total

1.  Excess risk of colon cancer associated with a polymorphism of the APC gene?

Authors:  R L White
Journal:  Cancer Res       Date:  1998-09-15       Impact factor: 12.701

2.  The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice.

Authors:  K Moriya; H Fujie; Y Shintani; H Yotsuyanagi; T Tsutsumi; K Ishibashi; Y Matsuura; S Kimura; T Miyamura; K Koike
Journal:  Nat Med       Date:  1998-09       Impact factor: 53.440

3.  Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas.

Authors:  K Watanabe; O Tachibana; K Sata; Y Yonekawa; P Kleihues; H Ohgaki
Journal:  Brain Pathol       Date:  1996-07       Impact factor: 6.508

Review 4.  The oncogenic activation of beta-catenin.

Authors:  P Polakis
Journal:  Curr Opin Genet Dev       Date:  1999-02       Impact factor: 5.578

5.  Beta-catenin mutation in carcinoma of the uterine endometrium.

Authors:  T Fukuchi; M Sakamoto; H Tsuda; K Maruyama; S Nozawa; S Hirohashi
Journal:  Cancer Res       Date:  1998-08-15       Impact factor: 12.701

Review 6.  Pathogenesis of hepatitis B and C-induced hepatocellular carcinoma.

Authors:  R Idilman; N De Maria; A Colantoni; D H Van Thiel
Journal:  J Viral Hepat       Date:  1998-09       Impact factor: 3.728

Review 7.  Inactivation of the E-cadherin-mediated cell adhesion system in human cancers.

Authors:  S Hirohashi
Journal:  Am J Pathol       Date:  1998-08       Impact factor: 4.307

8.  Childhood hepatoblastomas frequently carry a mutated degradation targeting box of the beta-catenin gene.

Authors:  A Koch; D Denkhaus; S Albrecht; I Leuschner; D von Schweinitz; T Pietsch
Journal:  Cancer Res       Date:  1999-01-15       Impact factor: 12.701

9.  Beta-catenin mutations in human prostate cancer.

Authors:  H J Voeller; C I Truica; E P Gelmann
Journal:  Cancer Res       Date:  1998-06-15       Impact factor: 12.701

10.  Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas.

Authors:  A de La Coste; B Romagnolo; P Billuart; C A Renard; M A Buendia; O Soubrane; M Fabre; J Chelly; C Beldjord; A Kahn; C Perret
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-21       Impact factor: 11.205

View more
  79 in total

1.  Methylation status of c-fms oncogene in HCC and its relationship with clinical pathology.

Authors:  J Cui; D H Yang; X J Bi; Z R Fan
Journal:  World J Gastroenterol       Date:  2001-02       Impact factor: 5.742

Review 2.  Wnt Signaling in vascular eye diseases.

Authors:  Zhongxiao Wang; Chi-Hsiu Liu; Shuo Huang; Jing Chen
Journal:  Prog Retin Eye Res       Date:  2018-12-01       Impact factor: 21.198

Review 3.  Beta-catenin signaling, liver regeneration and hepatocellular cancer: sorting the good from the bad.

Authors:  Kari Nichole Nejak-Bowen; Satdarshan P S Monga
Journal:  Semin Cancer Biol       Date:  2010-12-21       Impact factor: 15.707

4.  Molecular mechanism of iron metabolism and overload in chronic hepatitis C.

Authors:  Masahiko Kaito
Journal:  J Gastroenterol       Date:  2007-01       Impact factor: 7.527

5.  Effect of mutant β-catenin on liver growth homeostasis and hepatocarcinogenesis in transgenic mice.

Authors:  Timothy J Stein; Adam Jochem; Katie E Holmes; Eric P Sandgren
Journal:  Liver Int       Date:  2011-01-19       Impact factor: 5.828

6.  Pegylated interferon alpha targets Wnt signaling by inducing nuclear export of β-catenin.

Authors:  Michael D Thompson; Mohd Jamal Dar; Satdarshan P S Monga
Journal:  J Hepatol       Date:  2010-10-29       Impact factor: 25.083

Review 7.  Genetics of hepatocellular carcinoma.

Authors:  Andreas Teufel; Frank Staib; Stephan Kanzler; Arndt Weinmann; Henning Schulze-Bergkamen; Peter-R Galle
Journal:  World J Gastroenterol       Date:  2007-04-28       Impact factor: 5.742

Review 8.  Molecularly targeted therapy for advanced hepatocellular carcinoma - a drug development crisis?

Authors:  Kiruthikah Thillai; Paul Ross; Debashis Sarker
Journal:  World J Gastrointest Oncol       Date:  2016-02-15

Review 9.  Wnt signaling in liver cancer.

Authors:  Yutaka Takigawa; Anthony M C Brown
Journal:  Curr Drug Targets       Date:  2008-11       Impact factor: 3.465

Review 10.  DNA markers in molecular diagnostics for hepatocellular carcinoma.

Authors:  Ying-Hsiu Su; Selena Y Lin; Wei Song; Surbhi Jain
Journal:  Expert Rev Mol Diagn       Date:  2014-08-07       Impact factor: 5.225

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.